Aescap

Over Aescap

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time.

The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines.

Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

The funds are managed by an experienced investment team with an excellent track record. The members of the investment team significally invest in the funds themselves.

The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.

Trefwoorden

• Active Management
• Article 8 Sfdr
• Asset Management
• Biotech
• Biotech Fonds
• Biotechfonds
• Esg
• Fund Management
• Gene Therapy
• Genetics
• Genetics Fund
• Healthcare
• Life Sciences
• Medicine
• Patrick Krol
• Public Biotech
• Rna

Adres

• Hoofdkantoor

  Arent Janszoon Ernststraat 595C1082LD AmsterdamNoord-Holland, Nederland

Team per functiegebied

Gebaseerd op 12 openbare functieprofielen, stand van 2 september 2026.

• Finance / Accounting5
• Data / Analytics / Science2
• Founder / Owner2
• Consulting / Advisory1
• Engineering / Software Development1
• Research / R&D1